1. 1OTrastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study. (24th November 2019) Authors: Huang, C; Yang, Y; Kwong, A; Chen, S-C; Tseng, L-M; Liu, M-C; Shen, K; Wang, S; Ng, T-Y; Feng, Y; Sun, G; Yan, I R; Shao, Z Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗